Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in ART

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by Shandong University.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
The First Affiliated Hospital of Zhengzhou University
IBSA Institut Biochimique SA
Second Hospital of Hebei Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Information provided by (Responsible Party):
Zijiang Chen, Shandong University
ClinicalTrials.gov Identifier:
NCT01107470
First received: April 20, 2010
Last updated: March 22, 2012
Last verified: April 2010
  Purpose

Age-related variability of the efficacy and tolerability of alternative pituitary suppression regimens in follicular stimulation for assisted reproduction purposes. A randomised, prospective, multi-centre clinical trial


Condition Intervention
Infertility
Drug: hFSH(Fostimon)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in Follicular Stimulation for Assisted Reproduction Purposes. A Randomised, Prospective, Multi-centre Clinical Trial

Resource links provided by NLM:


Further study details as provided by Shandong University:

Estimated Enrollment: 2000
Study Start Date: April 2010
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group A1
Age 18-34y (with short protocol)
Drug: hFSH(Fostimon)
After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
Group A2
age 35-42y ( with short protocol)
Drug: hFSH(Fostimon)
After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
Group B1
age 18-34y ( with long protocol)
Drug: hFSH(Fostimon)
After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
Group B2
age 35-42y ( with long protocol)
Drug: hFSH(Fostimon)
After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).

Detailed Description:

Pituitary suppression is strongly advised to be included within the follicular stimulation protocols to avoid the occurrence of a premature LH surge, which leads to cycle cancellation.

However, whatever the drug and the schedule selected to achieve it, it is clear that pituitary suppression constitute a major perturbation of the endocrine milieu and that it has an impact on the outcome of the stimulation.

Indeed, the data in the literature support the idea that pituitary down-regulation by GnRH agonists according to the so-called long protocol, resulting in a deeper suppression, result in better clinical outcomes as compared to the short protocol, at least in women of younger reproductive age. Conversely, it has been proposed that a less profound suppression (e.g. short protocol), that allows better background regulation from the pituitary, should be preferred in women of advanced reproductive age.

However, the majority of the data currently supporting the decision makers in selecting their pituitary suppression strategies is based on studies focussed on standard, good prognosis patients whereas just a few studies have specifically addressed the special issue of the advanced reproductive age. Inasmuch, very few data are available in pure (non resistant) advanced age patients and, however, no studies have compared in the same setting younger vs aged subjects with an adequate sample size.

Another intriguing aspect of the question is that the chronological age does not necessarily overlap with the reproductive age which, besides complicating the decisional process in the clinical practise, may also play as a confounding factor in the evaluation of the results from clinical trials. Several studies have validated the role of the so-called follicle antral count (AFC) and the anti-Mullerian hormone (AMH) circulating levels as having a predictive role in the evaluation of the actual reproductive age. In particular the latter, the AMH, appears to be easier to standardise and to be used as the best reference in multicentre clinical studies focussed on the reproductive age.

In summary, there is a clear lack of information on the performance of the different GnRH-agonist schedules in alternative chronological and reproductive age groups and the data from a large size prospective trial may generate valuable indications for the daily clinical practise.

  Eligibility

Ages Eligible for Study:   18 Years to 42 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients addressed to follicular stimulation for in vitro fertilisation purposes will constitute the study population.

Criteria

Inclusion Criteria:

  • Age 18 to 42
  • First IVF attempt
  • BMI 18 to 25
  • Basal FSH less than 12 for subjects below the age of 35 or less than 15 for subjects aged more than 35
  • Informed consent

Exclusion Criteria:

  • Genital malformation
  • Hypersensitivity to study drugs
  • Major illnesses (to be specified)
  • PCOS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01107470

Contacts
Contact: Zijiang Chen, professor +86-531-85187856 zjchen59@yahoo.com

Locations
China, Shandong
Shandong University reproductive medicine researche center Recruiting
Jinan, Shandong, China, 250000
Contact: Zijiang Chen, professor    +86-531-85187856    zjchen59@yahoo.com   
Principal Investigator: Zijiang Chen, professor         
Sponsors and Collaborators
Shandong University
The First Affiliated Hospital of Zhengzhou University
IBSA Institut Biochimique SA
Second Hospital of Hebei Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Investigators
Study Director: Zijiang Chen, Professor Director of Shandong University reproductive medicine study center
  More Information

No publications provided

Responsible Party: Zijiang Chen, Professor, Shandong University
ClinicalTrials.gov Identifier: NCT01107470     History of Changes
Other Study ID Numbers: chenzj
Study First Received: April 20, 2010
Last Updated: March 22, 2012
Health Authority: China: Ethics Committee

Keywords provided by Shandong University:
Infertility IVF ART

Additional relevant MeSH terms:
Infertility
Genital Diseases, Female
Genital Diseases, Male

ClinicalTrials.gov processed this record on November 25, 2014